Raloxifene, a Mixed Estrogen Agonist/Antagonist, Induces Apoptosis through Cleavage of BAD in TSU-PR1 Human Cancer Cells*
Kim H, Kim B, Kim I, Mamura M, Seong H, Jang J, Kim S. Raloxifene, a Mixed Estrogen Agonist/Antagonist, Induces Apoptosis through Cleavage of BAD in TSU-PR1 Human Cancer Cells*. Journal Of Biological Chemistry 2002, 277: 32510-32515. PMID: 12084714, DOI: 10.1074/jbc.m202852200.Peer-Reviewed Original ResearchMeSH KeywordsAmino Acid Chloromethyl KetonesAntineoplastic AgentsApoptosisBcl-Associated Death ProteinBcl-X ProteinCarrier ProteinsCaspase 3CaspasesCell DivisionCell MembraneCell NucleusCycloheximideCytochrome c GroupDNA FragmentationDose-Response Relationship, DrugEstrogen Receptor ModulatorsHumansIn Situ Nick-End LabelingMembrane PotentialsMitochondriaPhosphorylationProtein BindingProtein Synthesis InhibitorsProto-Oncogene Proteins c-bcl-2Raloxifene HydrochlorideRetroviridaeTime FactorsTumor Cells, CulturedUrinary Bladder NeoplasmsConceptsMixed estrogen agonist/antagonistTSU-Pr1 cell linesEstrogen agonist/antagonistTSU-Pr1 cellsAgonists/antagonistsCell linesSelective estrogen receptor modulatorsHuman bladder transitional cell carcinoma cell lineEffects of raloxifeneTransitional cell carcinoma cell linesProstate cancer cell linesEstrogen receptor modulatorsCell carcinoma cell linesEstrogen receptor betaHuman bladder cancerDose-dependent mannerEvidence of apoptosisCancer cell linesRaloxifene treatmentCarcinoma cell linesBladder cancerReceptor modulatorsBreast cancerHuman cancer cellsRaloxifene